<DOC>
	<DOCNO>NCT00404885</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy LX211 therapy subject active non-infectious anterior uveitis</brief_summary>
	<brief_title>A Multi-center Study Assess Efficacy Safety LX211 Active Non-infectious Anterior Uveitis</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Uveitis , Anterior</mesh_term>
	<mesh_term>Iridocyclitis</mesh_term>
	<mesh_term>Panuveitis</mesh_term>
	<criteria>Documented history noninfectious anterior , anterior intermediate panuveitis Currently uncontrolled uveitis minimum 2 week despite use oral and/or topical corticosteroid , subject intolerant local corticosteroid therapy due development ocular hypertensive response subject oral corticosteroid contraindicate . Grade 2+ high anterior chamber cell time enrollment Considered investigator require corticosteroidsparing therapy . Subjects plan undergo elective ocular surgery study Uveitis infectious etiology Presence ocular toxoplasmosis scar An immune suppression regimen include alkylating agent within previous 90 day</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>uveitis</keyword>
	<keyword>calcineurin</keyword>
	<keyword>inflammation</keyword>
</DOC>